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Summary. Carriers of haemophilia face difficult
choices regarding prenatal diagnosis, but little is
known about the determinants that influence their
decisions. The aim of this study was to assess the
incidence of prenatal diagnosis and potential determi-
nants affecting the choice for prenatal diagnosis. A
nationwide survey was performed among all women
who underwent carriership testing for haemophilia in
the Netherlands between 1992 and 2004. Prenatal
diagnosis was assessed in 207 carriers of haemophilia
A or B who had been pregnant. Prenatal diagnosis was
categorized into early first trimester (Y-PCR testing or
chorionic villus sampling) often intended to prevent the
birth of a child with haemophilia, and into late
prenatal diagnosis (amniocentesis or ultrasound assess-
ment) aimed at obstetrical management. Of 207
carriers 112 (54%) underwent prenatal diagnosis.
Forty-eight women underwent early prenatal diagnosis
and 64 women underwent late prenatal diagnosis. In
26 pregnancies early prenatal diagnosis was positive
for haemophilia, and in 18 of these pregnancies
termination was opted for. The choice for early
prenatal diagnosis was associated with a liberal view
towards termination of pregnancy (relative risk (RR)
12.5; 95% confidence interval (CI) 3.1–51.2), severe
haemophilia in the family (RR 20.2; CI 2.7–153.6),
absence of a religion (RR 1.9; CI 1.1–3.1) and older
age (RR 2.0; CI 1.0–3.9). The choice for late prenatal
diagnosis was associated with birth year after 1970
(RR 2.3; CI 1.5–3.5) and a previous child with
haemophilia (RR 2.2; CI 1.4–3.4). More than half of
all Dutch haemophilia carriers underwent prenatal
diagnosis. Several determinants were strongly associ-
ated with prenatal diagnosis.
Keywords: amniocentesis, carriers, chorionic villus biopsy,
foetal gender determination, reproductive choices, termi-
nation of pregnancy
Introduction
Haemophilia is an X-linked recessive inherited bleeding
disorder that arises from reduced levels of functional
coagulation factor VIII (haemophilia A) or factor IX
(haemophilia B). Both types of haemophilia are rare
diseases, with prevalence of 1 in 5000 male live births
for haemophilia A and 1 in 30 000 for haemophilia B
[1]. The residual plasma concentration of the coagula-
tion factor determines the bleeding phenotype and
severe haemophilia is characterized by spontaneous
haemorrhages into muscles and joints, leading to
significant morbidity [2]. In spite of the advances made
in the management for haemophilia, a definite cure is
still lacking so that haemophilia remains a chronic and
incurable condition [3,4].
Prenatal diagnosis for haemophilia plays a pivotal
role in the genetic counselling for couples who are at
risk of having an affected child. Prenatal diagnosis may
be offered for two reasons: either to prevent the birth of
a child with haemophilia by early termination of an
affected pregnancy or to determine the need for specific
obstetrical precautions [5,6].
Couples at risk considering prevention of the birth
of a child with haemophilia are offered early inva-
sive prenatal diagnosis. DNA analysis on foetal
cells obtained by chorionic villus sampling or by
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amniocentesis has been available from the mid-1980s
onwards. Both methods are associated with a 0.5–1.0%
risk of procedure-related miscarriage [7]. Chorionic
villus sampling can be performed at 11–14 weeks of
gestation and therefore allows a diagnosis of an affected
pregnancy in the first trimester. Amniocentesis, how-
ever, can only be performed in the 16–17th week of
gestation. Chorionic villus sampling is therefore pre-
ferred over amniocentesis when termination of an
affected pregnancy is considered [8,9]. More recently,
the determination of the foetal gender in the 7–11th
weeks of pregnancy became available by analysis of free
foetal DNA isolated from maternal blood [8,10–12].
Using this so-called Y-PCR testing in female foetuses,
invasive procedures and associated risks can be avoided.
Another method for prenatal diagnosis is the direct
measurement of clotting factor activity in foetal blood
by cordocentesis (i.e. percutaneous umbilical cord blood
sampling). However, its use in the last two decades has
been limited to rare situations in which other techniques
are not available or in which other techniques yielded
inconclusive results [9].
Couples at risk who do not wish to prevent the
birth of an affected child are offered foetal gender
determination later in the pregnancy. In case of a
male foetus, the use of invasive foetal monitoring
during the delivery and instrumental delivery is
restricted to diminish the foetal bleeding risk. Ultra-
sound assessment allows reliable foetal gender deter-
mination in the second trimester [9]. This may be
followed by a late amniocentesis in the third trimes-
ter to determine the haemophilia status of a male
foetus [6].
Carriers of haemophilia face difficult choices regard-
ing reproduction and prenatal diagnosis, and these
complex decisions are likely to be influenced by
psychological, cultural and ethical factors [13–16].
Relatively little is known about carriers’ attitudes and
other determinants that influence prenatal diagnosis for
haemophilia. More knowledge on these issues may
improve quality of counselling, and may allow better
informed reproductive and obstetric choices for couples
at increased risk for having a child with haemophilia.
In the present nationwide cross-sectional study, our
aim was to assess how many carriers of haemophilia in
the Netherlands had undergone prenatal diagnosis, to
summarize the used methods and outcomes of prenatal
diagnosis, and to evaluate potential determinants affect-
ing the choice for prenatal diagnosis.
Material and methods
Study population
This study is based on data from a nationwide postal
survey conducted in 2004 among all women who
underwent carrier testing for haemophilia A or B in
the Netherlands during the period 1992–2004 [17]. The
survey was part of the Haemophilia in the Netherlands-
5 (HiN-5) study, which was designed to study attitudes
and consequences concerning haemophilia, haemophilia
carriership and haemophilia treatment.
Women aged 18 years or older participated in this
survey. The questionnaire was sent to all 766 women who
underwent carriership testing for haemophilia A or B in
the Netherlands between 1992 and 2004. Carriership for
haemophilia was assessed at either of two centres, the
Department of Clinical Genetics of the Leiden University
Medical Center or at the Van Creveldkliniek and
Department of Clinical Genetics of the University Med-
ical Center Utrecht. Of these 766 women, 546 (71%)
responded and completed the questionnaire. Carriers of
haemophilia who had been pregnant at least once after
carrier testing, and thus had faced the choice for prenatal
diagnosis for haemophilia in at least one pregnancy were
eligible for this study. We therefore excluded women who
were non-carriers (n = 245), women with an unknown or
inconclusive carrier status (n = 10), women with clotting
disorders other than haemophilia (n = 19), women who
had never been pregnant (n = 43) and carriers with a son
with isolated haemophilia who did not become pregnant
again after carrier testing (n = 22). This left 207 women
for the present analyses.
Data collection
The questionnaire collected data on demographic char-
acteristics, number of pregnancies and children, reli-
gion, type and perceived severity of haemophilia in the
family and methods and outcomes of prenatal diagno-
sis. In addition, bleeding tendency was recorded using a
validated questionnaire on a variety of bleeding symp-
toms [18]. The carrier status, clotting factor level and
type and severity of haemophilia in the family were
verified at the haemophilia treatment centres.
The study was approved by the Committee of
Medical Ethics of the Leiden University Medical Center.
All participants gave informed consent.
Definitions
Carriers of haemophilia were women in whom a gene
mutation causing haemophilia A or B was shown by
DNA analysis or in whom linkage analysis showed
carriership, women who were obligate carriers based on
pedigree analysis, and women for whom a high prob-
ability of carriership was calculated based on pedigree
analysis and clotting factor levels. Non-carriers were
women in whom testing (DNA analysis, pedigree
analysis and clotting factor levels) showed that they
did not carry the causative mutation or the related
haplotype.
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Prenatal diagnosis was defined as any form of testing
for haemophilia or for foetal gender during pregnancy.
Prenatal diagnosis was categorized into first trimester
early prenatal diagnosis (i.e. chorionic villus sampling
and Y-PCR testing) and prenatal diagnosis performed
later in pregnancy (i.e. ultrasound assessment and amnio-
centesis). This classification was chosen, because only
women considering termination of an affected pregnancy
were offered early prenatal diagnosis by chorionic villus
sampling, which in later years was preceded by Y-PCR
testing. In contrast, late prenatal diagnosis by ultrasound
assessment and third trimester amniocentesis was offered
to determine the need for specific obstetric precautions.
The only exception to this is second trimester amniocen-
tesis, which may be performed in view of terminating an
affected pregnancy rather than to determine the manage-
ment during delivery. However, in our dataset the
distinction between second and third trimester amnio-
centesis was not possible.
Severity of bleeding tendency of carriers was graded
with a bleeding score ranging from 0 to 4; the higher the
bleeding score, the higher the bleeding tendency
[17,18]. The disease severity of haemophilia in the
family was categorized according to the residual plasma
activities of factor VIII or IX in index patients: severe
(<0.01 IU mL)1), moderate (0.01 – 0.05 IU mL)1), and
mild (>0.05–0.40 IU mL)1) haemophilia [19]. Educa-
tional level was categorized into three categories:
primary and lower secondary, upper secondary and
tertiary level. Age at time of first pregnancy was
categorized into three categories: 16–25 years, 26–
30 years and 31–40 years.
Data analysis
The associations between putative determinants and the
choice for prenatal diagnosis were assessed by calculat-
ing the ratio of cumulative incidences, referred to as
relative risks (RR) and 95% confidence intervals (CI) in
women who underwent early first trimester prenatal
diagnosis and in women who underwent prenatal
diagnosis later in pregnancy. Relative risks were
adjusted for age at time of first pregnancy by the
Mantel–Haenzel method. Factors considered to be
associated with the choice for prenatal diagnosis are
shown in Table 4 and 5. The subgroup of women who
were carriers of severe haemophilia were analysed
separately because we considered that their reasons to
perform prenatal diagnosis were quite different from
carriers of moderate and mild haemophilia. We did not
correct for multiple testing, considering that valid
associations would be missed by making adjustments
for multiple testing [20].
Other survey data were analysed using descriptive
statistical methods. Data are presented as medians
and interquartile range (IQR) when not normally
distributed.
Results
Study population
The characteristics of the study population are described
in Table 1. Of the 207 women, 175 (85%) women were
carriers of haemophilia A, and the majority (84%) had a
positive family history of haemophilia. One hundred and
three (50%) women were carriers of severe haemophilia
and 113 (55%) carriers had one or more sons with
haemophilia. The median age at time of the question-
naire was 41 years (IQR 35–39 years). One hundred and
eight (52%) women reported to adhere to a particular
religion, including Roman Catholic (n = 52), Protestant
(n = 51), Hindu (n = 3), Muslim (n = 1) and an unspec-
ified religion (n = 1). Table 1 also shows the character-
istics of the subgroups of carriers who underwent early
prenatal diagnosis and carriers who underwent prenatal
diagnosis later in pregnancy.
Carriership diagnosis
One hundred and sixteen (56%) carriers were identified
via DNA analysis, whereas for 70 (34%) women the
probability of carriership was calculated based on
pedigree analysis and clotting factor levels. The remain-
ing 21 (10%) women did not remember the method of
carrier testing. The median age at time of carrier testing
was 30 years (IQR 26–35 years).
Prevalence of prenatal diagnosis
Of the 207 carriers, 112 women (54%) underwent
prenatal diagnosis during at least one pregnancy. Median
age at time of first prenatal diagnosis was 29 years (IQR
26–32 years). Forty-eight women underwent early pre-
natal diagnosis via chorionic villus sampling or Y-PCR
testing. In all pregnancies together, these women under-
went 85 chorionic villus sampling and 5 Y-PCR testing
procedures (Table 2). Sixty-four women underwent late
prenatal diagnosis with ultrasound assessment or amnio-
centesis. In all their pregnancies, there were 78 ultra-
sound assessments and 27 amniocentesis procedures
(Table 2). Prenatal diagnosis by cordocentesis was not
reported by any of the women. One woman underwent
pre-implantation genetic diagnosis for haemophilia.
Of the 112 women who underwent prenatal diagnosis,
58 (52%) carriers were tested during more than one
pregnancy. Thirty-three carriers underwent prenatal diag-
nosis during two pregnancies, of whom 30 (91%) had the
same prenatal test each time: ultrasound assessment
(n = 22), chorionic villus sampling (n = 6) and amnio-
centesis (n = 2). Three women had different methods, of
whom one switched from early to late prenatal diagnosis.
Twenty-five carriers underwent prenatal diagnosis
during three pregnancies, of whom 20 (80%) had the
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same method for prenatal diagnosis each time: chorionic
villus sampling (n = 14), ultrasound assessment (n = 5)
and amniocentesis (n = 1). Five carriers had different
tests, of whom three switched from late to early prenatal
diagnosis and two from early to late prenatal diagnosis.
Frequencies of the prenatal diagnosis methods applied
for the first and second time were similar. For the third
time, however, the percentage of early prenatal diagno-
sis (72%) was higher as compared to the first (40%) and
second (45%) time of testing. Of the 17 women who
underwent chorionic villus sampling for a third time, a
majority (82%) underwent chorionic villus sampling the
previous two times of prenatal diagnosis.
Of the women who never had prenatal diagnosis,
three (3%) women indicated they would choose for
either invasive or non-invasive prenatal diagnosis in a
future pregnancy, 56 (59%) would not and 36 (38%)
did not know yet.
In the subgroup of carriers of severe haemophilia the
prevalence of prenatal diagnosis was 67% (69 of 103).
Of these 69 carriers, 40 women underwent early
prenatal diagnosis and 29 women prenatal diagnosis
later in pregnancy.
Outcomes of prenatal diagnosis
Early prenatal diagnosis via chorionic villus sampling or
Y-PCR testing was applied in 90 pregnancies. In 22
pregnancies chorionic villus sampling was positive for a
male foetus with haemophilia, and in 18 (82%) of these
pregnancies termination of pregnancy was opted for
(Table 3). Seventeen of these cases concerned severe
haemophilia and the other case involved moderate
haemophilia. Three women had terminations of two
pregnancies of a male foetus with haemophilia, and
these women were all carriers of severe haemophilia. Of
the four pregnancies with an affected foetus that were
continued to term, three had severe haemophilia and
one had moderate haemophilia.
Table 1. Personal characteristics for all carriers of haemophilia (n = 207),
for the carriers who had early prenatal diagnosis (n = 48) and the carriers
who had late prenatal diagnosis (n = 64).
All
carriers
Carriers who underwent
prenatal diagnosis
Early prenatal
diagnosis
Late prenatal
diagnosis§
Number of women 207 48 64
Age at time of
questionnaire in years
41 (35–49) 40 (35–46) 36 (32–41)
Missing data 2 2 0
Number of pregnancies 2.5 (1–4) 3 (2–4) 2 (2–3)
Missing data 1 0 0
Age at time of first
pregnancy
26 (24–26) 28 (25–28) 27 (25–27)
Children (%)
Yes 205 (99) 47 (98) 64 (100)
No 2 (1) 1 (2) 0 (0)
Number of children 2 (2–3) 2 (1–3) 2 (1–3)
Marital status (%)
Married, including
registered partnership
160 (77) 40 (83) 51 (80)
Unmarried, including
single, divorced and
widowed women
47 (23) 8 (17) 13 (20)
Religion (%)
Yes 108 (52) 18 (38) 35 (55)
No 94 (46) 30 (63) 27 (42)
Missing data 5 (2) 0 (0) 2 (3)
Highest completed educational levels
Primary level 12 (6) 3 (6) 7 (11)
Lower secondary level 61 (29) 9 (19) 17 (26)
Upper secondary level 78 (38) 18 (38) 24 (38)
Tertiary level 54 (26) 17 (35) 16 (24)
Missing data 2 (1) 1 (2) 0 (0)
Family history of haemophilia
Yes 174 (84) 41 (85) 54 (84)
No 30 (15) 7 (15) 9 (14)
Missing data 3 (1) 0 (0) 1 (2)
Son with haemophilia (%)
Yes 113 (55) 20 (42) 35 (55)
No 94 (45) 28 (58) 29 (45)
Type of haemophilia in the family (%)
Haemophilia A 175 (85) 42 (88) 54 (84)
Haemophilia B 21 (10) 4 (8) 6 (9)
Unknown/missing data 11 (5) 2 (4) 4 (6)
Severity of haemophilia in the family (%)
Severe 103 (50) 40 (83) 29 (45)
Moderate 28 (14) 5 (10) 11 (17)
Mild 50 (24) 1 (2) 14 (22)
Unknown/missing data 26 (12) 2 (4) 10 (15)
Times opted for prenatal diagnosis
Never 95 (46) 0 (0) 0 (0)
One time 54 (26) 22 (46) 32 (50)
Two times 33 (16) 10 (21) 23 (36)
Three times 25 (12) 16 (33) 9 (14)
Values are presented as numbers (%) of the no. of women or medians
(interquartile range) when appropriate.
Defined as in extended family members, not including son(s).
Early prenatal diagnosis includes chorionic villus sampling and Y-PCR
testing.
§Late prenatal diagnosis includes ultrasound assessment and amniocentesis.
Table 2. Used methods and outcomes for prenatal diagnosis executed for a
first, second or third time.
Use of prenatal diagnosis
1st time
(n = 112)
2nd time
(n = 58)
3rd time
(n = 25)
Total
(n = 195)
Methods of prenatal diagnosis
Early prenatal diagnosis 46 (41) 26 (45) 18 (72) 90 (46)
Chorionic villus sampling 43 (38) 25 (43) 17 (68) 85 (43)
Foetal gender assessment
via Y-PCR testing
3 (3) 1 (2) 1 (4) 5 (3)
Late prenatal diagnosis 66 (59) 32 (56) 7 (28) 105 (54)
Foetal gender assessment
via ultrasound
49 (44) 27 (47) 2 (8) 78 (40)
Amniocentesis 17 (15) 5 (9) 5 (20) 27 (14)
Outcomes of prenatal diagnosis
Daughter 59 (53) 24 (41) 9 (36) 92 (47)
Son with unknown status 30 (27) 16 (28) 3 (12) 49 (25)
Son without haemophilia 9 (8) 10 (17) 3 (12) 22 (11)
Affected son with
haemophilia
10 (9) 8 (14) 8 (32) 26 (13)
Others* 4 (3) 0 (0) 2 (8) 6 (3)
Termination of
pregnancy for
haemophilia
6 (5) 8 (14) 4 (16) 18 (9)
Values are presented as numbers (%) of the no. of pregnancies.
*Twins, miscarriage, inconclusive results of prenatal diagnosis, or
congenital disorders other than haemophilia.
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There were 105 pregnancies in which late prenatal
diagnosis was applied. In 27 pregnancies invasive prena-
tal diagnosis was applied. Of these, four (4%) pregnan-
cies were positive for a son with haemophilia. Three of
these positive tested pregnancies were demonstrated by
amniocentesis following ultrasound assessment, and one
pregnancy by amniocentesis only. All four affected
pregnancies were continued to term. Of these, two had
severe, one had moderate and one had mild haemophilia.
Seven women had termination of pregnancy for
reasons other than haemophilia, including termination
of pregnancy for a male foetus with trisomy 21, and
termination of pregnancy for a female foetus with
Turner syndrome and haemophilia.
Reported reasons pro and against prenatal diagnosis
Among the women who underwent early prenatal
diagnosis, the most frequently reported reasons to
undergo prenatal diagnosis were: the carrier’s prefer-
ence to know if she was pregnant of a child with
haemophilia (93%), because of an increased risk for a
child with a congenital disorder other than haemophilia
(3%), the physician’s preference to know the haemo-
philia status of the child (2%) and other reasons (2%).
Women who underwent late prenatal diagnosis
reported the following reasons to undergo prenatal
diagnosis: the carrier’s preference to know if she was
pregnant with a child with haemophilia (41%), the
physician’s preference to know the haemophilia status
of the child (32%), because of an increased risk for a
child with a congenital disorder other than haemophilia
(8%) and other reasons (20%).
Among the 95 women who never had prenatal diagno-
sis, the four most cited reasons were: accepting the
possibility of having a child with haemophilia (28%), fear
for foetal loss due to prenatal diagnosis (16%), being
opposed to undergo termination of pregnancy (14%) and
perceiving the haemophilia in the family as not severe
enough (13%). Less frequently reported reasons were: fear
for foetal damage due to prenatal testing (11%), finding
haemophilia not a good reason for prenatal diagnosis
(6%), not being aware of the possibility of prenatal
diagnosis (6%), because of religious belief (4%), because
the partner was against prenatal diagnosis (2%) and
finding the risk of having an affected child too small (2%).
For carriers of severe haemophilia the reported pros
and cons for prenatal diagnosis were similar. Reported
reasons for prenatal diagnosis were: the carrier’s pref-
erence to know if she was pregnant of a child with
haemophilia (80%), the physician’s preference to know
the haemophilia status of the child (9%), because of an
increased risk for a child with a congenital disorder
other than haemophilia (6%) and other reasons (5%).
The following reasons con prenatal diagnosis reported
by carriers of severe haemophilia were: accepting the
possibility of having a child with haemophilia (31%),
fear for foetal loss due to prenatal diagnosis (20%),
being opposed to undergo termination of pregnancy
(16%), fear for foetal damage due to prenatal testing
(12%), not being aware of the possibility of prenatal
diagnosis (5%), finding haemophilia not a good reason
for prenatal diagnosis (5%), because the partner was
against prenatal diagnosis (3%), perceiving the haemo-
philia in the family not severe enough (3%), because of
religious belief (3%) and finding the risk of having an
affected child too small (2%).
Factors associated with decisions for prenatal
diagnosis
Table 4 presents the associations of several determi-
nants with the choice for early prenatal diagnosis and
the choice for late prenatal diagnosis in all carriers. The
choice for early prenatal diagnosis was associated with:
a liberal view towards termination of pregnancy, severe
haemophilia in the family and having no religion.
Compared to women aged 16–25 years at time of
first pregnancy, older women (26–30 years and 31–
40 years) opted more often for prenatal diagnosis.
Smaller positive associations were found for being
married, presence of a previous child with haemophilia,
a higher educational level and a higher bleeding score.
Year of birth and having family members with haemo-
philia did not influence the choice for early prenatal
diagnosis. After adjustment for age at time of first
pregnancy, the adjusted relative risks did not differ from
the crude relative risks.
The choice for late prenatal diagnosis was associated
with two determinants: a previous child with haemo-
philia and year of birth. Women born after 1970 were
2.3 times (CI 1.5–3.5) more likely to undergo late
prenatal diagnosis than women born before 1970. In
contrast, women with a liberal view towards termina-
tion of pregnancy tended to opt less often for late
prenatal diagnosis.
Total number of pregnancies, total number of chil-
dren, family relationship to nearest family member with
haemophilia and the perceived importance of haemo-
philia in family planning were not associated with the
choice for prenatal diagnosis (data not shown).
Association between potential determinants and testing
among carriers of severe haemophilia are shown in
Table 3. Termination of pregnancy for pregnancies positive for haemo-
philia according to early or late prenatal diagnosis.
Prenatal diagnosis
Early Late
Termination of
pregnancy
Yes 18* (82) 0 (0)
No 4 (18) 4 (100)
Total number of
affected pregnancies
22 4
Values are presented as numbers (%) of the no. of pregnancies.
*Three carriers underwent the procedure for termination of pregnancy two
times.
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Table 5. The findings among carriers of severe haemo-
philia did not substantially differ from those among all
carriers. However, among carriers of severe haemophilia
higher bleeding score, higher educational level, and having
family members with treatment-related viral infections did
not show any association with early prenatal diagnosis.
Discussion
In this nationwide cross-sectional study among 207
Dutch carriers of a factor VIII or IX gene mutation, 112
(54%) women had chosen for prenatal diagnosis of
haemophilia. Forty-eight (23%) carriers had undergone
early prenatal diagnosis via Y-PCR testing or chorionic
villus sampling in the first trimester. In these women 22
pregnancies were positive for an affected male foetus, and
in 18 (82%) of these cases the pregnancy was terminated.
A liberal view towards termination of pregnancy, severe
haemophilia in the family, older age at time of first
pregnancy and having no religion were associated with
the choice for first trimester prenatal diagnosis. Sixty-
four (31%) carriers had prenatal diagnosis later during
pregnancy via amniocentesis or ultrasound assessment.
Among these, four pregnancies were positive for haemo-
Table 4. Determinants influencing the choice for prenatal diagnosis made by all carriers of haemophilia (n = 207).
All carriers
Prenatal diagnosis Early prenatal diagnosis§ Late prenatal diagnosis–
Determinant
Early§
(n = 48)
Late–
(n = 64)
No
(n = 95) Total
Crude
RR (CI)
Adjusted
RR*(CI)
Crude
RR (CI)
Adjusted
RR*(CI)
Marital status
Unmarried** 8 (17) 13 (28) 26 (55) 47 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Married 40 (25) 51 (32) 69 (43) 160 1.5 (0.7–2.9) 1.4 (0.7–2.8) 1.2 (0.7–2.0) 1.1 (0.7–1.9)
Age at time of first pregnancy
16–25 years 14 (16) 24 (28) 48 (56) 86 1 (ref) NA 1 (ref) NA
26–30 years 23 (28) 26 (31) 34 (41) 83 1.7 (0.9–3.1) NA 1.1 (0.7–1.8) NA
31–40 years 11 (32) 14 (41) 9 (27) 34 2.0 (1.0–3.9) NA 1.5 (0.9–2.5) NA
Year of birth
Before 1970 37 (22) 42 (26) 85 (52) 164 1 (ref) 1 (ref) 1 (ref) 1 (ref)
After 1970 9 (22) 22 (54) 10 (24) 41 1.0 (0.5–1.9) 1.0 (0.5–2.0) 2.1 (1.4–3.1) 2.3 (1.5–3.5)
Highest completed educational level
Primary/lower
secondary level
12 (16) 24 (33) 37 (51) 73 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Upper secondary level 18 (23) 24 (31) 36 (46) 78 1.4 (0.7–2.7) 1.4 (0.7–2.9) 0.9 (0.6–1.5) 0.9 (0.5–1.4)
Tertiary level 17 (31) 16 (30) 21 (39) 54 1.9 (1.0–3.7) 1.7 (0.7–4.4) 0.9 (0.5–1.5) 0.8 (0.4–1.4)
Religion
Yes 18 (17) 35 (33) 54 (50) 107 1 (ref) 1 (ref) 1 (ref) 1 (ref)
No 30 (32) 27 (29) 37 (39) 94 1.9 (1.1–3.2) 1.9 (1.1–3.1) 0.9 (0.6–1.3) 0.8 (0.5–1.2)
View regarding termination for pregnancy for haemophilia
Neutral 2 (5) 13 (33) 25 (63) 40 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Against termination
of pregnancy
0 (0) 32 (46) 37 (54) 69 0 0 1.4 (0.9–2.4) 1.3 (0.8–2.3)
Not against termination
of pregnancy
40 (63) 12 (19) 12 (19) 64 12.5 (3.2–48.9) 12.5 (3.1–51.2) 0.6 (0.3–1.1) 0.6 (0.3–1.2)
Bleeding score
0 15 (19) 24 (30) 41 (51) 80 1 (ref) 1 (ref) 1 (ref) 1 (ref)
1 18 (23) 25 (32) 34 (44) 77 1.2 (0.7–2.3) 1.2 (0.7–2.3) 1.1 (0.7–1.7) 1.1 (0.7–1.7)
2–4 15 (30) 15 (30) 20 (40) 50 1.6 (0.9–3.0) 1.6 (0.9–3.0) 1.0 (0.6–1.7) 1.0 (0.6–1.7)
Severity of haemophilia in family
Mild 1 (2) 14 (28) 35 (70) 50 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Moderate 5 (18) 11 (39) 12 (43) 28 8.9 (1.1–72.7) 8.3 (1.1–65.5) 1.4 (0.7–2.7) 1.4 (0.8–2.7)
Severe 40 (39) 29 (28) 34 (33) 103 19.4 (2.7–137.2) 20.2 (2.7–153.6) 1.0 (0.6–1.7) 0.9 (0.5–1.6)
Family members with haemophilia
No 7 (23) 9 (30) 14 (47) 30 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 41 (24) 54 (31) 79 (45) 174 1.0 (0.5–2.0) 0.9 (0.5–1.9) 1.0 (0.6–1.9) 1.0 (0.6–1.9)
Previous child with haemophilia
No 39 (21) 50 (27) 94 (51) 183 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 9 (38) 14 (58) 1 (4) 24 1.8 (1.0–3.2) 1.9 (1.1–3.5) 2.1 (1.4–3.2) 2.2 (1.4–3.4)
Family members with treatment–related viral infections
No 21 (16) 41 (32) 67 (52) 129 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 27 (35) 23 (30) 28 (36) 78 2.1 (1.3–3.5) 2.1 (1.3–3.4) 0.9 (0.6–1.4) 0.9 (0.6–1.4)
Values are presented as numbers (%) of the no. of women.
*Adjusted for age at time of first pregnancy.
Not including son(s).
HIV or hepatitis infection, including in deceased family members.
§Early prenatal diagnosis includes Y-PCR testing and chorionic villus sampling.
–Late prenatal diagnosis includes ultrasound assessment and amniocentesis.
**Including single, divorced and widowed women.
CVS, chorionic villus sampling; 95% CI, confidence interval; NA, not applicable, Ref, reference; RR, relative risk.
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philia, and all four were continued to term. A previous
child with haemophilia and year of birth were associated
with the choice for late prenatal diagnosis.
To appreciate these findings, several limitations need to
be considered. First, a self-reported postal questionnaire
may be influenced by recall bias, which may lead to
underestimation of the proportion of women undergoing
prenatal diagnosis. However, considering the emotional
stress accompanying Y-PCR testing, chorionic villus
sampling, amniocentesis and the decision to terminate
an affected pregnancy, invasive prenatal testing proce-
dures are not likely to be forgotten. Also, this is not likely
to be associated with determinants of choosing for
prenatal diagnosis. Ultrasound assessment, however,
may have been underreported so that the prevalence of
non-invasive prenatal testing via ultrasound assessment
may be underestimated. In addition, ultrasound assess-
ments as reported by the carriers may have been
performed for reasons other than prenatal diagnosis of
haemophilia. Although there is an open attitude towards
termination of affected pregnancies in the Netherlands,
we cannot completely rule out that there was an
underreporting of termination of pregnancies. Second,
the determinants affecting the choice for prenatal testing
were measured after the actual choice for prenatal
diagnosis, and determinants may have changed over time
and differ at the time of choosing for prenatal diagnosis.
Still, attitudes towards prenatal diagnosis and termina-
tion of pregnancy are likely to remain stable over time
[21]. Third, our study results involved women who
Table 5. Determinants influencing the choice for prenatal diagnosis made by carriers of severe haemophilia (n = 103).
Determinant
Severe carriers
Prenatal diagnosis Early prenatal diagnosis§ Late prenatal diagnosis–
Early§
(n = 40)
Late–
(n = 29)
No
(n = 34)
Total Crude
RR (CI)
Adjusted
RR*(CI)
Crude
RR (CI)
Adjusted
RR*(CI)
Marital status
Unmarried** 6 (26) 5 (22) 12 (52) 23 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Married 34 (43) 24 (30) 22 (28) 80 1.6 (0.8–3.4) 1.5 (0.7–3.1) 1.4 (0.6–3.2) 1.3 (0.5–3.2)
Age at time of first pregnancy
16–25 years 12 (29) 10 (24) 19 (46) 41 1 (ref) NA 1 (ref) NA
26–30 years 17 (46) 11 (30) 9 (24) 37 1.6 (0.9–2.8) NA 1.2 (0.6–2.5) NA
31–40 years 11 (46) 8 (33) 5 (21) 31 1.6 (0.8–3.0) NA 1.4 (0.6–3.0) NA
Year of birth
Before 1970 33 (40) 20 (24) 30 (36) 83 1 (ref) 1 (ref) 1 (ref) 1 (ref)
After 1970 6 (32) 9 (47) 4 (21) 19 0.8 (0.4–1.6) 0.9 (0.4–1.8) 2.0 (1.1–3.6) 2.4 (1.2–4.8)
Highest completed educational level
Primary/lower
secondary level
11 (34) 7 (22) 14 (44) 32 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Upper secondary level 13 (30) 15 (34) 16 (36) 44 0.9 (0.4–1.7) 0.9 (0.4–1.8) 1.6 (0.7–3.4) 1.5 (0.7–3.5)
Tertiary level 16 (62) 7 (27) 3 (12) 26 1.8 (1.0–3.2) 1.9 (0.8–4.9) 1.2 (0.5–3.1) 1.4 (0.5–4.4)
Religion
Yes 16 (33) 15 (31) 18 (37) 49 1 (ref) 1 (ref) 1 (ref) 1 (ref)
No 24 (47) 14 (27) 13 (25) 51 1.4 (0.8–2.4) 1.4 (0.8–2.4) 0.9 (0.5–1.7) 0.8 (0.5–1.6)
View regarding termination of pregnancy for haemophilia
Neutral 1 (6) 4 (22) 13 (72) 18 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Against termination
of pregnancy
0 (0) 15 (54) 13 (46) 28 0 0 2.4 (1.0–6.2) 2.2 (0.8–6.2)
Not against termination
of pregnancy
33 (79) 6 (14) 3 (7) 42 14.1 (2.1–95.6) 14.9 (1.8–121.0) 0.6 (0.2–2.0) 0.7 (0.2–2.3)
Bleeding score
0 13 (35) 11 (30) 13 (35) 37 1 (ref) 1 (ref) 1 (ref) 1 (ref)
1 16 (42) 11 (29) 11 (29) 38 1.2 (0.7–2.1) 1.2 (0.7–2.2) 1.0 (0.5–2.0) 1.0 (0.5–2.1)
2–4 11 (39) 7 (25) 10 (36) 28 1.1 (0.6–2.1) 1.1 (0.6–2.0) 0.8 (0.4–1.9) 0.9 (0.4–2.0)
Family members with haemophilia
No 6 (25) 7 (29) 11 (46) 24 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 34 (43) 22 (28) 23 (29) 79 1.7 (0.8–3.6) 1.9 (0.9–3.8) 1.0 (0.5–2.0) 1.1 (0.5–2.3)
Previous child with haemophilia
No 32 (37) 21 (24) 33 (38) 86 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 8 (47) 8 (47) 1 (6) 17 1.3 (0.7–2.2) 1.4 (0.7–2.5) 1.9 (1.0–3.6) 1.9 (1.0–3.7)
Family members with treatment-related viral infections
No 18 (33) 17 (32) 19 (35) 54 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 22 (45) 12 (24) 15 (31) 49 1.3 (0.8–2.2) 1.3 (0.8–2.1) 0.8 (0.4–1.5) 0.8 (0.4–1.4)
Values are presented as numbers (%) of the no. of women.
*Adjusted for age at time of first pregnancy.
Not including son(s).
HIV or Hepatitis infection, including in deceased family members.
§Early prenatal diagnosis includes Y-PCR testing and chorionic villus sampling.
–Late prenatal diagnosis includes ultrasound assessment and amniocentesis.
**Including single, divorced and widowed women.
CVS, chorionic villus sampling; 95% CI, confidence interval; Ref, reference; RR, relative risk.
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underwent carrier testing in the Netherlands during the
period 1992–2004. Since then, advances in prenatal
diagnosis have been made, particularly in the develop-
ment of non-invasive foetal gender determination via
analysis of free foetal DNA obtained from maternal
blood. In addition, treatment options for haemophilia
have improved over the years. This should be taken into
account when our results are translated into clinical
implications for current-day practice.
A strength of our study is its relatively high response-
rate of 71%. The results of the survey are therefore
likely to be representative for all carriers of haemophilia
in the Netherlands at time of this study. Selection bias is
not likely to have influenced our results, however, we
cannot exclude this.
A majority (54%) of the carriers underwent carrier
testing for haemophilia in view of family planning.
However, in our study carriers had an average of two
children. This figure is comparable with women in the
general Dutch population in the same period, for whom
the mean number of children during the same period
was two (Statistics Netherlands; http://statline.
cbs.nl). These figures are also in line with data from
Sweden, in which carriers were found to have the same
number of children as other women of similar age [21].
Also, mean age at time of first pregnancy did not differ
between carriers and women in the general Dutch
population (27 years vs. 28 years respectively).
Womenwhounderwent chorionicvillus samplingandY-
PCR testing likely had the intention to terminate an affected
pregnancy. Indeed, in our study these women had under-
gone termination of pregnancy in a substantial proportion
(82%)of theaffectedpregnancies.Only four (18%)women
undergoing chorionic villus sampling decided to continue
their affected pregnancy to term. In addition, the choice
for chorionic villus sampling and Y-PCR testing was
strongly associated with a liberal view towards termination
of pregnancy. In contrast, ultrasound assessment and
amniocentesis are rather applied to assess the need for
precautions during pregnancy and delivery. In concordance
with this view, in our study none of the women who
underwent late prenatal diagnosis had termination of
pregnancy for a pregnancy affected with haemophilia.
The majority (85%) of our study group had known
haemophilia in the family. Therefore, the results may
not be directly applicable to sporadic carriers of
haemophilia. These women may differ from the spo-
radic carriers in their choices, attitudes and determi-
nants of prenatal diagnosis.
During the 12 year-study period the availability and
accepted practice of the different methods of prenatal
diagnosis have evolved. For instance, foetal gender
determination by Y-PCR testing has become available
only in the last few years. Despite these changes, a
majority (86%) of the women who underwent prenatal
diagnosis for more than one pregnancy had the same
method of prenatal diagnosis each time.
The prevalence of prenatal diagnosis found in this
study is not directly comparable with figures found in
previous studies due to differences in both the study
population and the applied definition of prenatal
diagnosis. Including only chorionic villus sampling, in
our study the proportion of women who opted for
prenatal diagnosis was 22%. In a Dutch survey
conducted in 1987 among 218 obligate and potential
carriers who had ever been pregnant, 11% had opted
for invasive prenatal diagnosis, and 31% would have
opted for prenatal diagnosis if termination between the
8th and 10th week of pregnancy could be realized
[13]. In Sweden, 14% of 376 known carriers in 1994
underwent prenatal diagnosis by foetal blood sampling
or by chorionic villus sampling [21]. In 1996, a survey
held in London among 197 obligate and potential
carriers of haemophilia reported that 36 out of 160
(23%) women who had been pregnant had opted for
invasive prenatal diagnosis [15]. It seems that the
proportion of carriers opting for invasive prenatal
diagnosis with the aim to undergo termination of
pregnancy in case of haemophilia found in our study is
comparable with that from previous studies, despite
developments in genetic counselling and prenatal
diagnosis. First, the availability of prenatal diagnosis
has become more widespread, and carriers may be
better informed about prenatal diagnosis for haemo-
philia. Second, Y-PCR testing in early pregnancy may
prelude chorionic villus sampling in case of a female
foetus. On the other hand, the demand for early
invasive prenatal diagnosis with the aim of preventing
the birth of a child with haemophilia may have
decreased because of improved treatment options and
a lowered perceived disease severity for haemophilia
[21]. In our study, 39 women did not opt for prenatal
diagnosis because they either accepted the possibility
of a child with haemophilia or they did not find
haemophilia a sufficiently severe disease. A decrease in
invasive testing has been shown in two studies among
English carriers, in whom the percentage of invasive
prenatal diagnosis for haemophilia decreased from
35% during 1985–1995 to 20% in 1995–2005
[22,23]. The frequency of invasive prenatal diagnosis
for haemophilia may decrease further, when foetal
gender determination by non-invasive methods such as
Y-PCR testing in maternal blood is introduced on a
large scale [24,25]. In addition, pre-implantation
genetic diagnosis may serve as an alternative for
prenatal diagnosis, although this procedure requires
in vitro fertilization that is still associated with
disadvantages at the moment [26]. Sperm sorting for
X-carrying sperm may be another alternative method
to avoid an affected pregnancy [27]. Moreover, current
research is directed to develop non-invasive tests to
diagnose the gene mutation causing haemophilia
directly in free foetal DNA obtained from maternal
blood [28].
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The proportion of carriers undergoing ultrasound
assessment in our study was 21%. This proportion is
quite low, considering that currently every carrier in the
Netherlands is offered ultrasound assessment to allow
planning of the management during delivery. Also, offer-
ing amniocentesis in the third trimester for obstetric
reasons has been a recent development. In concordance
with this view, women born after 1970 tended to have
ultrasound assessment and amniocentesis more frequently.
Ultrasound for gender determination is now advised to all
carriers who did not have early prenatal diagnosis.
In the present study a number of determinants were
associated with the choice for prenatal diagnosis.
Several of these determinants associated with the choice
for prenatal diagnosis were previously described by
others, such as having a liberal view towards termina-
tion of pregnancy, perceiving haemophilia as a severe
disease and adhering to a religion [13,21].
In conclusion, we have described the prevalence,
methods and outcomes of prenatal diagnosis and several
determinants of the choice of prenatal diagnosis made by
female carriers of haemophilia. Our results will be helpful
in improving the genetic counselling given to carriers at
increased risk of having a child with haemophilia.
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